Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

David L. Kendler, Fernando Marin, Cristiano A. F. Zerbini, Luis A. Russo, Susan L. Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Peter Lakatos, Astrid Fahrleitner-Pammer, Eric Lespessailles, Salvatore Minisola, Jean Jacques Body, Piet Geusens, Ruediger Moricke, Pedro Lopez-Romero

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)230-240
Number of pages11
JournalLancet
Volume391
Issue number10117
DOIs
Publication statusPublished - 20 Jan 2018

Keywords

  • LOW BONE MASS
  • VERTEBRAL FRACTURES
  • ZOLEDRONIC ACID
  • ALENDRONATE
  • DENOSUMAB
  • PLACEBO
  • RISK
  • BMD

Cite this